Alicia H. Augustine, Ph.D.

About Me

Alicia Augustine is the Associate Director for Research in the Center for Human Experimental Therapeutics (CHET) and a Research Assistant Professor in the Department of Community and Preventive Medicine. CHET carries out the mission of conducting hypothesis-driven, rigorously designed, initial inve...

Alicia Augustine is the Associate Director for Research in the Center for Human Experimental Therapeutics (CHET) and a Research Assistant Professor in the Department of Community and Preventive Medicine. CHET carries out the mission of conducting hypothesis-driven, rigorously designed, initial investigations of novel therapeutic interventions for human diseases, and is the T1 Key Function within the Clinical and Translational Science Institute. In her role as Associate Director, Dr. Augustine is responsible for collaborative initiation and maintenance of research projects within CHET, as well as engaging with University of Rochester investigators regarding research design and implementation of early phase clinical studies. Additional responsibilities include representation of CHET within the Clinical and Translational Science Institute and co-coordination/instruction of the Experimental Therapeutics course (PM488). Her primary research interests include pre-clinical experimentation and early-phase trial design.

Faculty Appointments

Adjunct Assistant Professor - Department of Neurology, Center for Health and Technology (SMD)

Credentials

Post-doctoral Training & Residency

Post-doctoral fellow, Preventive Cardiology, University of Rochester School of Medicine and Dentistry 2010 - 2011

Education

MS | University of Rochester School of Medicine and Dentistry. Clinical Investigation. 2011

PhD | University of Rochester School of Medicine and Dentistry. Pathology. 2009

BS | Delaware Valley College. Biology. 2002

Publications

Journal Articles

Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse.

Clementi AH, Gaudy AM, Zimmers TA, Koniaris LG, Mooney RA

Metabolism: clinical and experimental.. 2011 November 60 (11):1610-9. Epub 05/31/2011.

Suppressor of cytokine signaling-3 is a glucagon-inducible inhibitor of PKA activity and gluconeogenic gene expression in hepatocytes.

Gaudy AM, Clementi AH, Campbell JS, Smrcka AV, Mooney RA

The Journal of biological chemistry.. 2010 December 31285 (53):41356-65. Epub 10/26/2010.

Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling.

Clementi AH, Gaudy AM, Rooijen NV, Pierce RH, Mooney RA

Biochimica et biophysica acta.. 2009 November 1792 (11):1062-72. Epub 08/20/2009.

Interleukin-6 depletion selectively improves hepatic insulin action in obesity.

Klover PJ, Clementi AH, Mooney RA

Endocrinology.. 2005 August 146 (8):3417-27. Epub 04/21/2005.